Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New vaccine platform may fight infections with causes from influenza to bioterrorism

24.11.2005


Researchers from Children’s Hospital of Pittsburgh, University of Pittsburgh and Louisiana State University report findings in Journal of Clinical Investigation

The development of effective vaccines for people with compromised immune systems may be feasible after all, according to a team of researchers, who demonstrated their approach could protect against pneumocystis pneumonia in mice lacking the same population of immune cells that HIV destroys in humans. The vaccine platform developed by Children’s Hospital of Pittsburgh researchers, working in collaboration with researchers from the University of Pittsburgh and Louisiana State University, suggests that the immune system can be primed to ward off other infections as well, such as those caused by the flu, smallpox or exposure to anthrax, even in patients who have the highest risk for infection.

Reporting in the Journal of Clinical Investigation, Jay K. Kolls, MD, division chief of Pediatric Pulmonology, Laboratory of Lung Immunology and Host Defense at Children’s Hospital of Pittsburgh, and professor of Pediatrics and Immunology at the University of Pittsburgh School of Medicine, and co-authors describe how their vaccine consisting of a specific antigen to pneumocystis and a molecule normally expressed on activated T-cells of the immune system offers protection from infection even in the absence of essential immune cells.



Pneumocystis is a common and very serious infection in people with deficient function of CD4+ T-cells, such as patients with transplanted organs, HIV and children with leukemia. Without normal reservoirs of these particular T-cells that are key to immune responses, these patients are unable to stave off an infection that in most people causes, at most, a bad cold.

The findings are being published in the December 1 issue of the journal. The manuscript will be available online after 5 p.m. Nov. 23, 2005, at www.jci.org.

"In addition to protection against pneumocystis, our vaccine platform may be effective in preventing viral illnesses such as influenza, in high-risk, immune-deficient individuals," Dr. Kolls said. "This new technology opens up the possibility that therapeutic vaccine response can be achieved in populations of patients who face the greatest risk – children, the immunosuppressed and the elderly.

Although not discussed in the paper, Dr. Kolls says the vaccine approach is worth investigating its potential for offering protection against weaponized agents, such as anthrax.

In mice depleted of CD4+ T cells, which are essential for signaling other cells and for producing antigen-specific antibodies, the vaccine strategy provided protection against pneumocystis. Importantly, this vaccine strategy was able to bypass the need for T cells.

A series of experiments helped identify the two key components of the experimental DNA vaccine, so called because it has only the molecular signatures of these constructs: the molecule used by activated CD4+ T cells to signal production of antibodies, and importantly, the specific fragment of pneumocystis that receptors on these antibodies recognize.

The researchers first identified as key CD40L, a molecule expressed on activated CD4+ T cells that in turn signals other cells, including B cells, to produce antibodies against the pathogen. But antibodies rely on other cells, such as dendritic cells, to capture the antigen and advertise their bounty, which they do by displaying an antigen fragment on their cell surface. Antibodies see this antigen fragment as a mug shot of sorts, and when they recognize the same fragment expressed on the on the infecting organism the antibodies give phagocytic cells the OK to consume, or eliminate, the pathogen. Through their studies, the researchers discovered a particularly potent fragment of pneumocystis, the kexin molecule, which when isolated yielded greater antibody response than pneumocystis as a whole.

In perhaps the most significant experiments the researchers conducted, mice depleted of CD4+ T cells received the combination CD40L-kexin vaccine in three doses administered three weeks apart. Three weeks later, they were infected with pneumocystis. Upon examination, the vaccinated mice had significantly less organism in their lungs. According to the researchers, nearly 100 percent (999.999 percent) of the invading pneumocystis was thwarted by the vaccine-induced antibody-mediated process, compared to about 20 percent in animals that had not been vaccinated.

The number of people with compromised immune systems continues to rise, a population that cannot be protected against polio, the flu and other infectious agents with existing vaccines that depend on a normal T-cell response. As such, the researchers were motivated to develop CD4+ T-cell–independent therapeutic strategies to meet this growing need.

"While we’ll need to replicate these findings in larger animal models, our studies indicate it may be feasible to develop vaccines for bioterrorism agents and transplant patients, as well as high-risk individuals who have defective CD4+ T-cell function," Dr. Kolls said. "We are excited about the results because they indicate that we can engineer a vaccine to create a new protection for those who are immunosuppressed."

In addition to Dr. Kolls, other authors include Mingquan Zheng, M.D.; Chad Steele, Ph.D., and Florencia McAllister, M.D., all of Children’s Hospital and the department of pediatrics, University of Pittsburgh School of Medicine; Corrine Kliment, Christopher Crowe and Rekha R. Rapaka, University of Pittsburgh School of Medicine M.D.-Ph.D. students; Karen A. Norris, Ph.D., department of immunology, University of Pittsburgh School of Medicine; and Alistair J. Ramsey, Ph.D.; Myles B. Robichaux, M.S., Judd E. Shellito, M.D., and Paul Schwarzenberger, M.D., from Louisiana State University.

Melanie Finnigan | EurekAlert!
Further information:
http://www.chp.edu
http://www.jci.org

More articles from Life Sciences:

nachricht Ambush in a petri dish
24.11.2017 | Friedrich-Schiller-Universität Jena

nachricht Meadows beat out shrubs when it comes to storing carbon
23.11.2017 | Norwegian University of Science and Technology

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New proton record: Researchers measure magnetic moment with greatest possible precision

High-precision measurement of the g-factor eleven times more precise than before / Results indicate a strong similarity between protons and antiprotons

The magnetic moment of an individual proton is inconceivably small, but can still be quantified. The basis for undertaking this measurement was laid over ten...

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

IceCube experiment finds Earth can block high-energy particles from nuclear reactions

24.11.2017 | Physics and Astronomy

A 'half-hearted' solution to one-sided heart failure

24.11.2017 | Health and Medicine

Heidelberg Researchers Study Unique Underwater Stalactites

24.11.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>